SNDL (SNDL) shares gained nearly 12% on Wednesday. Dec. 16 following reports that President Donald Trump could reclassify cannabis as a “Schedule III” drug by the end of this week.
The U.S. government is considering a policy shift that would offer some seniors access to cannabis products under Medicare coverage as well, the reports added.
SNDL stock has been a volatile investment this year. Despite a sharp rally on Tuesday, it’s down more than 25% versus its year-to-date high in early October.
The potential reclassification of marijuana under the Trump administration is one of many catalysts that could drive SNDL shares higher over the next 12 months.
These include the firm’s recent agreement to acquire 32 of 1CM’s cannabis retail stores in Canada, potentially strengthening its market share heading into 2026.
Expanding its retail footprint, especially in key provinces like Ontario, Alberta, and Saskatchewan, could boost SNDL’s revenue over time.
Additionally, the Nasdaq-listed firm posted a record $16.7 million in free cash flow for its Q3 last month, which means it’s better positioned to pursue growth initiatives in the coming year.
Together with the expected policy tailwinds, these developments suggest SNDL is poised for further upside in 2026.
Valuation wise, SNDL stock is going for a price-sales multiple of less than 1x currently, making it an inexpensive name to play the cannabis industry’s long-term potential.
Plus, the recent rally has pushed SNDL well over $2, effectively eliminating the delisting risk that had weighed on the stock for months.
On Tuesday, the cannabis stock rallied past its 100-day moving average (MA) as well, indicating the uptrend could continue in the near term.
In fact, options traders are pricing in a more than 20% rally in SNDL shares through Jan. 16, which means they could be trading at $2.53 in early 2026.
According to Wall Street analysts, SNDL stock could more than double from here next year on the back of policy tailwinds.
The consensus rating on SNDL shares currently sits at “Moderate Buy” with the mean target of $4.75 indicating potential upside of another 120%.